Biotech entity
Colossal Biosciences is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 140-day window averages about 0.1 stories each week. Their average consequence score of 7.5 runs above the beat's 6.3 for that window. They are less corroborated than the beat average, carrying 3 original sources each against 4 for the same window.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Colossal Biosciences is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 140-day window averages about 0.1 stories each week. Their average consequence score of 7.5 runs above the beat's 6.3 for that window. They are less corroborated than the beat average, carrying 3 original sources each against 4 for the same window. The clearest coverage concentration is funding: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Biotech stories that mention Ben Lamm, published between March 4, 2026 and July 21, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 445 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ben Lamm. Shared-story counts are live from our verified record — not editorial picks.
Target Birth Date
Projected window for the birth of the first mammoth-elephant hybrid calf.
Funding talks reported at $20B–$30B valuation
Axios and TechCrunch report Colossal is in discussions to raise new capital at a valuation between $20 billion and $30 billion.
Tasmanian devil cancer partnership launched
Colossal Foundation partners with University of Tasmania to combat contagious facial cancer in Tasmanian devils.
Artificial womb tech expected ready in 2027
CEO Ben Lamm tells Rolling Stone the technology could be spun off for human fertility applications.
Bluebuck antelope added as sixth target species
Colossal expands de-extinction pipeline to include bluebuck antelope.
Astromech spinout achieves $2B valuation
AI-driven biology predictive modeling company reaches unicorn status just months after launch.
Dubai Biovault
Colossal announces the opening of a major genetic preservation facility in Dubai.
Colossal valued at $10.2B after dire wolf project reveal
Investors justify valuation based on broad technology platform, not just de-extinction.
Series B Funding
Total funding surpasses $225M, valuing the company at over $1 billion.
Dodo Project Announced
The company expands its portfolio to include the de-extinction of the dodo bird.
Company Launch
Colossal Biosciences officially launches with $15M in seed funding to revive the woolly mammoth.
Colossal Biosciences is reportedly eyeing a valuation of $20 to $30 billion — more than double its 2025 mark — as it transitions from a de-extinction curiosity into a broad gene-editing and AI platform with multiple revenue streams, spinouts in plastics and fertility tech, and growing conservation contracts.
Source: TechCrunch · Marina Temkin (us)
Colossal Biosciences is advancing its ambitious plan to 'de-extinct' the woolly mammoth using CRISPR technology, sparking intense debate over ecological ethics and resource allocation. While the company frames the project as a climate solution, critics argue it distracts from urgent conservation efforts for existing endangered species.
Source: iowapublicradio.org · wdiy.org
Ben Lamm is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
